***Background.*** In January 2013 New York University Langone Medical Center (NYULMC) initiated a Pediatric Antimicrobial Stewardship (ASP) program utilizing the prospective Audit and Feedback process. In an effort to standardize therapy and improve quality of care, members of ASP developed evidence-based guidelines for management of common Pediatric infections. Cycles of education and re-education were employed. Antibiograms were developed for each Pediatric Unit and specialty populations.

***Methods.*** Compliance, calculated by the percent of time interventions were accepted, was used as a measure of process change. Outcome data was measured by *Clostridium difficile* (C. diff) rates, Days of Therapy (DOT)/1,000 patient days and resistance patterns of bacteria, specifically *Staphylococcus aureus*, *Enterobacter cloacae*, and *Klebsiella pneumoniae*.

***Results.*** Within the first 12 months of PAS initiation, interventions were suggested in 19% of audited antimicrobials. Among ASP suggested interventions to primary teams, 91% were accepted by the medical team and management was adjusted. The combined Pediatric C. diff rate/1,000 hosptial admissions in the 12 months prior and after initiation of stewardship is 1.02 and 0.36, respectively. Between 2012 and 2013 we observed decrease in DOT for broad spectrum antibiotics meropenem, cefepime and piperacillin-tazobactam and significant decrease in ceftazidime (p = 0.03), vancomycin (p = 0.01) and gentamicin (p = 0.025) use. There was a significant (p = 0.001) increase in *S. aureus* susceptibility to amoxicillin-clavulanate, no change in *E.coli* sensitivities, and decrease in *K.pneumonia*sensitivity to ceftriaxone (p = 0.04), ceftazidime (p = 0.03), cefoxitin (p = 0.001) and pipercillin-tazobactam (p = 0.005).

***Conclusion.*** Following PAS implementation we observed high rates of compliance and a subsequent reduction in broad spectrum antibiotic use and C.diff rates. The development of guidelines for vancomycin and aminoglycoside use, including high dose extended interval aminoglycosides, may have contributed to the significant decrease in DOT for those antibiotics. We observed a favorable change in *S.aureus* antibiotic profile. The decrease in *K.pneumoniae* sensitivity was not surprising, given similar trends observed at NYULMC and NYC, an 'epicenter' of Klebsiella resistance.
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